DaVitaMIL:1DVA 61 Buyback Yield % is 11.03 as of Jul. 12, 2026, which is 4% below its 10-year median of 11.47. GuruFocus rates MIL:1DVA with a GF Score™ of 61/100 and a GF Value™ of €148.57 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 274 Healthcare Providers & Services companies, DaVita ranks better than 98.54% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for DaVita's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1DVA vs THC, EHC, ENSG: Buyback Yield % Comparison
For the Medical Care Facilities subindustry, DaVita's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaVita Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaVita's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where DaVita's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaVita (MIL:1DVA) has a Buyback Yield % of 11.03 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on DaVita and its competitors. This is near median its historical median of 11.47. According to the industry distribution chart, DaVita ranks #4 out of 274 companies in the Healthcare Providers & Services industry, placing it in the top 1.5%.
Is DaVita's Buyback Yield % too high?
DaVita's current Buyback Yield % of 11.03 is near median its 10-year median of 11.47. Based on the distribution chart, DaVita ranks #4 out of 274 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DaVita has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DaVita's Buyback Yield % compare to THC and EHC?
According to the Healthcare Providers & Services industry distribution chart, DaVita ranks #4 out of 274 companies for Buyback Yield %. This places DaVita in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on DaVita and its competitors. DaVita's current Buyback Yield % is 11.03, which is near median its own 10-year median of 11.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaVita stock overvalued right now?
Based on GuruFocus' analysis, DaVita (MIL:1DVA) is currently considered Significantly Overvalued. The stock's GF Value™ is €148.57, compared to a current price of €207.10 — trading 39.4% above its estimated fair value. The current Buyback Yield % is 11.03, which is near median its 10-year median of 11.47. DaVita's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For DaVita (MIL:1DVA), the current Buyback Yield % is 11.03 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaVita (MIL:1DVA) Overvalued in 2026?
Based on GuruFocus' analysis, DaVita stock appears to be overvalued.
The current stock price of €207.10 is trading 39.4% above its estimated GF Value™ of €148.57.
GuruFocus considers DaVita to be Significantly Overvalued.
Key valuation signals for MIL:1DVA:
Buyback Yield %: 11.03 (near median its 10-year median of 11.47)
GF Value™: €148.57 vs. price of €207.10 (39.4% above fair value)
No single metric tells the full story. See the MIL:1DVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
61GF Score
Get the complete analysis for MIL:1DVA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1DVA has been successfully added to your 
